AR081994A1 - Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres - Google Patents

Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres

Info

Publication number
AR081994A1
AR081994A1 ARP110102198A ARP110102198A AR081994A1 AR 081994 A1 AR081994 A1 AR 081994A1 AR P110102198 A ARP110102198 A AR P110102198A AR P110102198 A ARP110102198 A AR P110102198A AR 081994 A1 AR081994 A1 AR 081994A1
Authority
AR
Argentina
Prior art keywords
denotes
cyy
nyy
naphthyridin
atoms
Prior art date
Application number
ARP110102198A
Other languages
English (en)
Inventor
Dieter Dorsch
Guenter Hoelzemann
Christiane Amendt
Frank Zenke
Alfred Jonczyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44487155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081994(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR081994A1 publication Critical patent/AR081994A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)

Abstract

Reivindicación 1: Compuestos de la fórmula (1) en donde W1, W2, W3, W4 denota de modo independiente entre sí, N o CR3; W5 denota N o C, con preferencia, denota N o CR3, con mayor preferencia, denota N; Z denota C=C, NR4, C=N, O, S, CH, N=N o N=C, con preferencia, denota C=C, N(R4)CO, NR4, C=N, O, CON(R4), S, CH, N=N o N=C, con mayor preferencia, denota C=C, N(R4)CO, NR4, C=N, O, CON(R4), S, CH o N=N; R1 denota un arilo monocíclico que tiene 5, 6, 7, 8, 9 ó 10 átomos de C o un heteroarilo monocíclico que tiene 5, 6, 7, 8, 9, 10, 11, 12, 13 ó 14 átomos de C y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, cada uno de los cuales puede estar independientemente sustituido con al menos un sustituyente seleccionado del grupo que consiste en Y, Hal, CN, CF3 u OY; R2 denota H, Hal, A, -(CYY)n-OY, -(CYY)n-NYY, -(CYY)n-Het, SY, NO2, CN, COOY, -CO-NYY, -NY-COA, -NY-SO2A, -SO2-NYY, S(O)mA, -CO-Het, -O(CYY)n-OY, -O(CYY)n-NYY, -O(CYY)n-Het, -NH-COOA, -NH-CO-NYY, -NH-COO-(CYY)n-NYY, -NH-COO-(CYY)n-Het, -NH-CO-NH-(CYY)n-NYY, -NH-CO-NH(CYY)n-Het, -OCO-NH-(CYY)n-NYY, -OCO-NH-(CYY)n-Het, CHO, COA, =S, =NY, =O ó un arilo monocíclico que tiene 5, 6, 7, 8, 9 ó 10 átomos de C o un heteroarilo monocíclico que tiene 5, 6, 7, 8, 9, 10, 11, 12, 13 ó 14 átomos de C y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, donde cada uno de arilo monocíclico y heteroarilo monocíclico puede estar sustituido, de modo independiente, con al menos un sustituyente seleccionado del grupo que consiste en Y, Hal, CN, CF3 u OY; R3 denota H, OY, NYY, NY-COY, NY-CO-(CYY)n-OY, NY-COY-NYY, NY-(CYY)n-NYY, O-(CYY)n-NYY u O-(CYY)n-Het; R4 denota H, A, -(CYY)o-Het, -(CYY)o-NYY o -(CYY)o-OY; R5 denota H, A, OY, NYY o Het; Y denota H o A, con preferencia, en caso de -(CYY)n/o-Y denote adicionalmente H, A u OH; A denota alquilo no ramificado o ramificado que tiene 1, 2, 3, 4, 5, 6, 7, 8, 9 ó 10 átomos de C, en donde 1, 2, 3, 4, 5, 6 ó 7 átomos de H pueden estar reemplazados, de modo independiente entre sí, por Hal y/o en donde uno o dos grupos CH2 pueden estar reemplazados, de modo independiente entre sí, con un O, S, SO, SO2, un grupo -CY=CY- y/o un grupo -CºC-; de modo alternativo, A denota cicloalquilo con 3, 4, 5, 6, 7 ó 8 átomos de C; Het denota un heterociclo mono, bi- o tricíclico saturado o insaturado que tiene 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ó 20 átomos de C y 1, 2, 3, 4 ó 5 átomos de N, O y/o S, que puede estar sustituido con al menos un sustituyente seleccionado del grupo que consiste en Y, Hal, CN, CF3, OY; Hal denota F, Cl, Br o I; m denota 0, 1 ó 2, n denota 0, 1, 2, 3 ó 4; o denota 0, 1, 2, 3 ó 4, con preferencia, si Z es NR4, o adicionalmente denota 2, 3 ó 4; p denota 0, 1, 2 ó 3; q denota 0, 1, 2 ó 3; siempre que se excluyan los siguientes compuestos: (a) 2-(5-cloro-2-fluoro-fenil)-4-isoquinolin-4-il-[1,8]naftiridina, (b) 4-isoquinolin-4-iI-2-(6-metil-piridin-2-il)-[1,8]naftiridina, (c) 4-[2-(2-fluoro-fenil)-[1,8]naftiridin-4-il]-[2,7]naftiridin-1-ilamina, (d) 4-[2-(2,5-difluoro-fenil)-[1,8]naftiridin-4-il]-[2,7]naftiridin-1-ilamina, (e) N-{4-[2-(2-fluoro-fenil)-[1,8]naftiridin-4-il]-[2,7]naftiridin-1-il}-acetamida, (f) 2-(2-fluoro-fenil)-4-[2,7]naftiridin-4-il-[1,8]naftiridina, (g) 5-[2-(2-fluoro-fenil)-[1,8]naftiridin-4-il]-[2,7]naftiridin-1-ilamina, (h) 5-[2-(5-cloro-2-fluoro-fenil)-[1,8]naftiridin-4-il]-[1,7]naftiridina, (i) 4-[2-(5-cloro-2-fluoro-fenil)-[1,8]naftiridin-4-il]-[2,7]naftiridin-1-ilamina, y sus sales, solvatos, estereoisómeros y tautómeros fisiológicamente aceptables, incluyendo sus mezclas en todas las proporciones.
ARP110102198A 2010-06-28 2011-06-24 Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres AR081994A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006683 2010-06-28

Publications (1)

Publication Number Publication Date
AR081994A1 true AR081994A1 (es) 2012-10-31

Family

ID=44487155

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102198A AR081994A1 (es) 2010-06-28 2011-06-24 Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres

Country Status (21)

Country Link
US (1) US8791113B2 (es)
EP (1) EP2585461B1 (es)
JP (1) JP5826261B2 (es)
KR (1) KR20130038336A (es)
CN (1) CN102958930B (es)
AR (1) AR081994A1 (es)
AU (1) AU2011273931B2 (es)
BR (1) BR112012033241A2 (es)
CA (1) CA2803665C (es)
CL (1) CL2012003680A1 (es)
CO (1) CO6612243A2 (es)
EA (1) EA201300052A1 (es)
EC (1) ECSP13012408A (es)
ES (1) ES2792799T3 (es)
IL (1) IL223496A (es)
MX (1) MX2012014549A (es)
NZ (1) NZ603456A (es)
PE (1) PE20130376A1 (es)
PH (1) PH12012502391A1 (es)
SG (1) SG186855A1 (es)
WO (1) WO2012000595A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
AU2010344973B2 (en) * 2010-02-05 2016-06-16 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
WO2014052563A2 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103113369A (zh) * 2013-03-21 2013-05-22 云南大学 一种具有抗肿瘤活性的苯并[b][1,8]-萘啶-2-(1H)-亚胺衍生物及合成方法
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN104086543A (zh) * 2014-06-19 2014-10-08 湖南华腾制药有限公司 一种制备4-氯-1,8-二氮萘的方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
PL3560924T3 (pl) * 2015-04-02 2021-10-11 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3492461B1 (en) * 2016-07-29 2024-10-23 Shanghai Yingli Pharmaceutical Co. Ltd. Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3527570A4 (en) 2016-10-14 2020-04-15 Jiangsu Hengrui Medicine Co., Ltd. FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
JP2020500177A (ja) 2016-11-14 2020-01-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ３，４−ビピリジルピラゾール誘導体、およびその製造方法およびその医療応用
CN106810550A (zh) * 2017-01-10 2017-06-09 湖南华腾制药有限公司 一种萘啶衍生物的制备方法
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2018171611A1 (zh) * 2017-03-22 2018-09-27 江苏恒瑞医药股份有限公司 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US12486234B2 (en) 2019-04-24 2025-12-02 Children's Medical Center Corporation PAPD5 inhibitors and methods of use thereof
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN115485025A (zh) * 2020-02-28 2022-12-16 雷密克斯医疗公司 用于调节剪接的化合物和方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
CN112608327B (zh) * 2021-01-28 2021-11-02 河南大学 呋喃并喹啉衍生物、其制备方法及应用
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN114836384A (zh) * 2022-01-26 2022-08-02 安徽理工大学环境友好材料与职业健康研究院(芜湖) 一种三氯乙烯诱导人源肝细胞恶性转化的方法及其应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024163966A1 (en) 2023-02-03 2024-08-08 Tris Pharma, Inc. Low sodium oxybate once nightly composition
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
JP2002540206A (ja) 1999-03-11 2002-11-26 ニューロゲン コーポレイション アリールの縮合した２，４−二置換ピリジン：ｎｋ３受容体リガンド
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
AU2000241466A1 (en) 2000-04-07 2001-12-17 Dong-Pyo Hong Lottery type selling method and apparatus using computer network
EP1511738A4 (en) * 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
AU2003256783A1 (en) 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
ES2305744T3 (es) 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
CN1921864A (zh) 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
JP4865258B2 (ja) 2005-06-21 2012-02-01 キヤノン株式会社 １，８−ナフチリジン化合物及びそれを用いた有機発光素子
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US20100093738A1 (en) * 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
JP4751856B2 (ja) 2007-07-03 2011-08-17 本田技研工業株式会社 車体側部構造
EP2291376A2 (en) * 2008-07-03 2011-03-09 Merck Patent GmbH Naphthyridininones as aurora kinase inhibitors
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
AU2010344973B2 (en) * 2010-02-05 2016-06-16 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
ES2528441T3 (es) * 2010-02-22 2015-02-10 Merck Patent Gmbh Hetarilaminonaftiridinas
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate

Also Published As

Publication number Publication date
CO6612243A2 (es) 2013-02-01
KR20130038336A (ko) 2013-04-17
AU2011273931B2 (en) 2015-04-23
PH12012502391A1 (en) 2013-02-11
WO2012000595A1 (en) 2012-01-05
CL2012003680A1 (es) 2013-10-11
US20130102603A1 (en) 2013-04-25
EA201300052A1 (ru) 2013-06-28
JP2013529658A (ja) 2013-07-22
CA2803665C (en) 2019-03-05
US8791113B2 (en) 2014-07-29
MX2012014549A (es) 2013-02-07
CN102958930B (zh) 2018-04-27
CA2803665A1 (en) 2012-01-05
IL223496A (en) 2016-10-31
CN102958930A (zh) 2013-03-06
AU2011273931A1 (en) 2013-02-07
SG186855A1 (en) 2013-02-28
PE20130376A1 (es) 2013-03-30
EP2585461B1 (en) 2020-02-26
ES2792799T3 (es) 2020-11-12
EP2585461A1 (en) 2013-05-01
NZ603456A (en) 2014-08-29
JP5826261B2 (ja) 2015-12-02
ECSP13012408A (es) 2013-03-28
BR112012033241A2 (pt) 2016-11-16

Similar Documents

Publication Publication Date Title
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR082109A1 (es) Derivados de bipiridilo
AR087355A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
CO6160288A2 (es) Composiciones farmaceuticas que comprenden nilotinib o su sal
AR087841A1 (es) Derivados de tetrahidrotriazolopirimidina
RU2011100786A (ru) Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
AR061106A1 (es) Pteridinas sustituidas y composiciones farmaceuticas que las contienen.
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR081252A1 (es) Compuestos para el tratamiento del sindrome metabolico
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure